Effective Use of Ustekinumab in a Patient with Concomitant Psoriasis, Vitiligo, and Alopecia Areata

A 39-year-old South Asian woman with moderate chronic plaque psoriasis, vitiligo, and alopecia areata (AA) showed significant improvement in all three conditions after treatment with ustekinumab, an IL-12/23 inhibitor. Previous treatments, including etanercept for psoriasis and intralesional triamcinolone for vitiligo, were ineffective. Ustekinumab was administered at 90 mg subcutaneously at 0 and 4 weeks, then every 8 weeks. By week 16, her psoriatic lesions resolved completely, and by week 20, there was notable hair regrowth and repigmentation in vitiligo patches. The patient tolerated the treatment well without adverse effects, suggesting that IL-12/23 blockade could be a promising therapeutic strategy for patients with these autoimmune conditions. However, further studies are needed to confirm long-term safety and efficacy.